Physician profile
Sandra K Ruby
NPI 1104966803
$1,504.16
in general payments reported to CMS, 2019-2025
28 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $81.69 · 2021: $269 · 2022: $122 · 2023: $126 · 2024: $185 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $155.66 | 2019-2025 | Amyvid, Kisunla |
| Biogen, INC. | $151.86 | 2019-2025 | Vumerity, Avonex, Tysabri |
| Genentech USA, INC. | $131.24 | 2019-2024 | Ocrevus Zunovo |
| Mdd US Operations, LLC | $120.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $96.92 | 2019-2025 | |
| Ucb, INC. | $74.31 | 2023-2024 | Rystiggo |
| Allergan, INC. | $74.24 | 2019-2021 | |
| Abbvie INC. | $62.14 | 2021-2023 | Qulipta |
| Argenx US, INC. | $52.22 | 2022-2025 | Vyvgart Hytrulo |
| Amneal Pharmaceuticals LLC | $50.51 | 2024-2025 | Crexont, Rytary |
| Pfizer INC. | $48.05 | 2023-2025 | |
| Acorda Therapeutics, INC | $45.94 | 2019-2021 | |
| Celgene Corporation | $43.07 | 2021-2022 | |
| Tg Therapeutics, INC. | $42.01 | 2024 | |
| Csl Behring | $39.85 | 2019-2023 | Hizentra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $37.04 | 2021 | |
| Amgen INC. | $31.28 | 2025 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $28.63 | 2024 | Hyqvia |
| Emd Serono, INC. | $28.43 | 2019 | |
| Alnylam Pharmaceuticals INC. | $27.63 | 2022 | |
| Alexion Pharmaceuticals, INC. | $24.82 | 2022 | |
| Banner Life Sciences, LLC | $24.32 | 2024 | |
| Sunovion Pharmaceuticals INC. | $21.47 | 2021 | |
| Kyowa Kirin, INC. | $20.21 | 2020 | |
| Acadia Pharmaceuticals INC | $19.20 | 2025 | Nuplazid |
| Lundbeck LLC | $18.82 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.81 | 2024 | Rexulti |
| Genzyme Corporation | $16.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Ruby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.